Atorvastatin Improves Cardiac Lipid Metabolism in Spontaneous Hypertensive Rats and Ameliorates Cardiac Hypertrophy
SUN Ya-xun,HU Shen-jiang,ZHANG Zhi-jie,KANG Lan,ZHAO Xiao-yan,ZHENG Xia
DOI: https://doi.org/10.3969/j.issn.1673-7245.2006.08.012
2006-01-01
Abstract:Objective To investigate the effect of atorvastatin on cardiac lipid metabolism and cardiac hypertrophy. Methods SHR(n=6) and WKY(n=6) were given atorvastatin 50 mg/kg·d body weight by gavage. After 10 weeks, LV/BW ratio, serum free fatty acid(FFA), peroxisome proliferator-activated receptor α(PPARα) and carnitime palmitoyltransferase(CPT-Ⅰ) mRNA in myocardium were investigated. Results Serum and myocardial free fatty acid in SHR were higher than that in WKY(seurm FFA:SHR:798.2±38.0 vs WKY:354.7±27.7 nmol/L, P0.01); (myocardium:635.0±77.4 vs WKY:245.3±47.3 nmol/L, P0.01). The expression of PPARα and CPT-Ⅰ mRNA in myocardium in SHR was decreased as compared with those in WKY group(0.285±0.062 vs WKY: 0.478±0.093, P0.01; 0.795±0.139 vs WKY: 1.115±0.109, P0.01 respectively), VWI and TDM in SHR were greater than those in WKY (3.16±0.08 vs WKY: 2.99±0.10 g/kg, P0.05; 21.32±1.25 vs WKY: 18.18±0.75 μm, P0.01). Atorvastatin decreased serum fatty acid (571.0±40.8 vs control:798.2±38.0 nmol/L, P0.01) and free fatty acid in cardiac myocytes (287.7±57.7 vs control:635.0±77.4 nmol/L, P0.01). Meanwhile, the expression of PPARα and CPT-Ⅰ mRNA in myocardium in atorvastatin group were increased (PPARα mRNA: 0.457±0.075 vs control:0.285±0.062, P0.01; CPT-Ⅰ mRNA: 1.037±0.101 vs control: 0.795±0.139, P0.05) in associated with lower VWI and TDM(2.98±0.05 vs control:3.16±0.08 g/kg, P0.01; 18.91±1.05 vs control:21.32±1.25 μm, P0.05). Conclusion Atorvastatin may ameliorate cardiac hypertrophy by improves cardiac lipid metabolism in the SHR.